---
layout: post
title: "Sciwind Biosciences Partners with Pfizer China to Commercialize its Biased GLP-1 in China"
date: 2026-02-24T05:22:00+00:00
source: PR Newswire Releases
source_url: https://www.prnewswire.com/news-releases/sciwind-biosciences-partners-with-pfizer-china-to-commercialize-its-biased-glp-1-in-china-302695339.html
significance: 7.20
---

<p>HANGZHOU, China, Feb. 24, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences") today announced a strategic commercialization collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a new–generation cAMP–biased GLP–1 receptor agonist. Under...</p>

**Source:** [PR Newswire Releases](https://www.prnewswire.com/news-releases/sciwind-biosciences-partners-with-pfizer-china-to-commercialize-its-biased-glp-1-in-china-302695339.html)

**Published:** 2026-02-24 05:22:00 +0000

**Significance Score:** 7.20

[View original](https://www.prnewswire.com/news-releases/sciwind-biosciences-partners-with-pfizer-china-to-commercialize-its-biased-glp-1-in-china-302695339.html)
